In this context, an enhanced CD38- and CD47-targeted therapeutic approach that can promote innate immune cell-induced tumor killing potential and overcome anti-CD38 antibody resistance mechanisms may be effective in treating hematologic malignancies. The gene discussed is CD47; the disease is neoplasm.